RxDoctor Payments Data

Emily Skotte, APRN

Acute Care · Nashville, TNNPI 1770827354

Payments from drug & device makers

What this record shows

The money is spread across several categories — speaking fees (38.2%), travel and lodging and consulting fees — rather than concentrated in one kind of arrangement. 11 manufacturers reported payments, led by Pfizer at 34.3% of the total. Reporting peaked in 2024 at $8,412 and has fallen 64.2% since, to $3,011 in 2025. Among acute care clinicians in TN with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$11,523in general payments, 2019–2025

Across 30 payments — averaging $384.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$4K
  • Catalyst Pharmaceuticals, Inc.$3K
  • Exelixis Inc.$3K
  • Lantheus Medical Imaging, Inc.$700
  • Janssen Scientific Affairs, LLC$580
  • Daiichi Sankyo Inc.$153
  • plus $338 from 5 others

What the payments were for

  • Consulting fees$1,78015%
  • Speaking & faculty fees$4,40038%
  • Travel & lodging$3,88934%
  • Food & beverage$1,45413%

General payments by program year

22
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$11,523 in reported general payments places this provider in the 95th percentile of 738 acute care providers in Tennessee.

See all acute care providers in Tennessee

Medicare billing

Part B allowed, 2024
$48,759
Medicare patients
181
Services billed
603

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TagrissoOsimertinib Mesylate25$404,690
EliquisApixaban23$25,167
XareltoRivaroxaban11$10,953
Albuterol Sulfate HfaAlbuterol Sulfate18$498
Gabapentin28$465
Oxycodone Hcl21$398
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen21$375
Omeprazole24$361
Mirtazapine18$332
Levothyroxine Sodium27$305
Dexamethasone24$270
Prednisone45$269
Prochlorperazine Maleate17$231
Ondansetron OdtOndansetron14$224
Lidocaine-PrilocaineLidocaine/Prilocaine17$203

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$3,950$25,16723 claims
Johnson & JohnsonXarelto$22$10,95311 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 738 acute care providers in Tennessee.

Other acute care in Nashville

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →